SCHEMBL1929322

SCHEMBL1929322

CCc1oc(-c2ccc(C)cc2)nc1CO[C@H]1CCCC(COC(C)(Cc2ccccc2)C(=O)O)C1

nearest known ligand 0.45

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 20/20 0.45
PPARG P37231 15/20 0.41
PPARD Q03181 8/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1929321 1.00 PPARA (0.45) PPARAPPARGPPARD
SCHEMBL13844006 0.92 PPARA (0.38) PPARAPPARGPPARD
SCHEMBL1929657 0.92 PPARA (0.38) PPARAPPARGPPARD
SCHEMBL1929662 0.92 PPARA (0.38) PPARAPPARGPPARD
SCHEMBL1929316 0.92 PPARA (0.38) PPARAPPARGPPARD
SCHEMBL1929319 0.92 PPARA (0.38) PPARAPPARGPPARD
SCHEMBL13843997 0.92 PPARA (0.39) PPARAPPARGPPARD
SCHEMBL1930445 0.92 PPARA (0.39) PPARAPPARGPPARD
SCHEMBL1930447 0.92 PPARA (0.39) PPARAPPARGPPARD
SCHEMBL1929128 0.90 PPARA (0.40) PPARAPPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7956077-B2 2-{-3,′2-(phenyl)-oxazol-4-ylmethoxyl-cyclohexyl methoxy}-propionic acid derivatives used as peroxisome proliferator-activated receptor (PPAR) ligands for the treatment of hyperlipidemia and diabetes SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2011-06-07 US disclosed
US-20070197613-A1 2-{-3,'2-(PHENYL)-OXAZOL-4-YLMETHOXYL-CYCLOHEXYL METHOXY}-PROPIONIC ACID DERIVATIVES USED AS PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) LIGANDS FOR THE TREATMENT OF HYPERLIPIDEMIA AND DIABETES SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197613-A1 2-{-3,'2-(PHENYL)-OXAZOL-4-YLMETHOXYL-CYCLOHEXYL METHOXY}-PROPIONIC ACID DERIVATIVES USED AS PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) LIGANDS FOR THE TREATMENT OF HYPERLIPIDEMIA AND DIABETES PPARA, PPARG, PPARD PPARA 1/4885PPARG 2/4885PPARD 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.